Made of stem cells carefully differentiated into cardiomyocytes, the patches, which are about the size of a small coin and contain approximately 50 million cells, can expand in size with every contraction. They initially help the heart to compensate for lost pumping power, but hopefully will eventually integrate with the heart and effectively replace the damaged tissues.
The Imperial team already successfully tested the patches in lab rabbits and demonstrated a variety of signs of improvement in the rabbits’ cardiac abilities post-infarct. These include the left ventricle recovering its strength, normal ECG tracings, and blood vessels proliferating into the patches to feed the newly introduced tissue. All this happened within about a month following the implantation of the patches.
These results have provided the researchers with a green light to begin clinical trials, which will first test the safety of this approach and involve a small number of patients. Following this, it is expected that larger studies will evaluate the benefit of the therapy in humans.
The research was presented and upcoming studies announced at the British Cardiovascular Society’s conference in Manchester this week.